Literature DB >> 8814407

Surgery for hepatoblastoma in children.

J D Geiger1.   

Abstract

The survival of children with hepatoblastoma, the most common malignant tumor of the liver in children, has improved dramatically over the past 20 years. This progress has been made with advances in surgical technique and improved chemotherapy, primarily with adriamycin and cisplatin. Despite these advances, those patients who present with advanced disease have unsatisfactory survival. Continued refinement of liver surgery and chemotherapy, as well as the use of new techniques such as chemoembolization, immunotherapy, and molecular biology, should lead to improved survival in patients with advanced disease.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8814407     DOI: 10.1097/00008480-199606000-00016

Source DB:  PubMed          Journal:  Curr Opin Pediatr        ISSN: 1040-8703            Impact factor:   2.856


  5 in total

Review 1.  Recent advances: paediatric surgery.

Authors:  P D Losty
Journal:  BMJ       Date:  1999-06-19

2.  Transarterial chemoembolization in the treatment of hepatoblastoma in children.

Authors:  Thomas J Vogl; Albert Scheller; Ursula Jakob; Stefan Zangos; Medhat Ahmed; Mohamed Nabil
Journal:  Eur Radiol       Date:  2005-07-08       Impact factor: 5.315

Review 3.  Role of interventional radiology in managing pediatric liver tumors : Part 1: Endovascular interventions.

Authors:  Matthew P Lungren; Alexander J Towbin; Derek J Roebuck; Eric J Monroe; Anne E Gill; Avnesh Thakor; Richard B Towbin; Anne Marie Cahill; C Matthew Hawkins
Journal:  Pediatr Radiol       Date:  2018-01-23

4.  Efficacy of preoperative transcatheter arterial chemoembolization combined with systemic chemotherapy for treatment of unresectable hepatoblastoma in children.

Authors:  Masakazu Hirakawa; Akihiro Nishie; Yoshiki Asayama; Nobuhiro Fujita; Kousei Ishigami; Tatsurou Tajiri; Tomoaki Taguchi; Hiroshi Honda
Journal:  Jpn J Radiol       Date:  2014-06-13       Impact factor: 2.374

5.  LncRNA MIR205HG accelerates cell proliferation, migration and invasion in hepatoblastoma through the activation of MAPK signaling pathway and PI3K/AKT signaling pathway.

Authors:  Wei Zhang; Feng Liang; Qingfeng Li; Hong Sun; Fei Li; Zhibo Jiao; Jie Lei
Journal:  Biol Direct       Date:  2022-01-07       Impact factor: 4.540

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.